Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 0.43 |
| ▸ | JAK3 | P52333 | 19/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL984731 | 0.91 | JAK3 (0.45) | JAK2JAK3 | |
| SCHEMBL981064 | 0.90 | JAK3 (0.46) | JAK2JAK3 | |
| SCHEMBL983435 | 0.90 | JAK3 (0.40) | JAK2JAK3 | |
| SCHEMBL983691 | 0.90 | KDM4C (0.46) | JAK2JAK3KDM2BKDM4C | |
| SCHEMBL983115 | 0.89 | JAK3 (0.47) | JAK2JAK3 | |
| SCHEMBL983088 | 0.86 | JAK3 (0.46) | JAK2JAK3KDM4C | |
| SCHEMBL986033 | 0.86 | CSNK2A2 (0.38) | JAK2JAK3KDM2BKDM4C | |
| SCHEMBL986034 | 0.86 | CSNK2A2 (0.38) | JAK2JAK3KDM2BKDM4C | |
| SCHEMBL983194 | 0.85 | JAK3 (0.38) | JAK2JAK3 | |
| SCHEMBL983134 | 0.85 | JAK3 (0.46) | JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2247594-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009106531-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | JAK2 1660/4885JAK3 1732/4885KDM2B 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.